Want to see HK:2315 full AI Analyst Report?
Total Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has a market cap or net worth of HK$20.49B. The enterprise value is HK$13.44K.
Market CapHK$20.49B
Enterprise ValueHK$13.44K
Share Statistics
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding110,781,920
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 8.49%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)8.49%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee955.51K
Profits Per Employee130.30K
Employee Count1,443
Asset Turnover0.37
Inventory Turnover1.91
Valuation Ratios
The current PE Ratio of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is 100.0. Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s PEG ratio is 0.18.
PE Ratio100.0
PS Ratio9.20
PB Ratio5.83
Price to Fair Value5.83
Price to FCF44.91
Price to Operating Cash Flow49.60
PEG Ratio0.18
Income Statement
In the last 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had revenue of 1.38B and earned 173.20M in profits. Earnings per share was 0.43.
Revenue1.38B
Gross Profit1.05B
Operating Income278.60M
Pretax Income188.03M
Net Income173.20M
EBITDA419.49M
Earnings Per Share (EPS)0.43
Cash Flow
In the last 12 months, operating cash flow was 364.04M and capital expenditures -87.47M, giving a free cash flow of 276.57M billion.
Operating Cash Flow364.04M
Free Cash Flow276.57M
Free Cash Flow per Share2.50
Dividends & Yields
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change121.35%
50-Day Moving Average47.20
200-Day Moving Average43.56
Relative Strength Index (RSI)61.58
Average Volume (3m)488.12K
Important Dates
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H upcoming earnings date is Sep 2, 2026, TBA (Confirmed).
Last Earnings DateApr 27, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H as a current ratio of 2.31, with Debt / Equity ratio of 26.86%
Current Ratio2.31
Quick Ratio2.12
Debt to Market Cap0.03
Net Debt to EBITDA-2.33
Interest Coverage Ratio3.92
Taxes
In the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has paid 14.83M in taxes.
Income Tax14.83M
Effective Tax Rate0.08
Enterprise Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H EV to EBITDA ratio is 27.91, with an EV/FCF ratio of 41.45.
EV to Sales8.49
EV to EBITDA27.91
EV to Free Cash Flow41.45
EV to Operating Cash Flow31.62
Balance Sheet
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has HK$1.56B in cash and marketable securities with HK$584.09M in debt, giving a net cash position of HK$978.92M billion.
Cash & Marketable SecuritiesHK$1.56B
Total DebtHK$584.09M
Net CashHK$978.92M
Net Cash Per ShareHK$8.84
Tangible Book Value Per ShareHK$5.41
Margins
Gross margin is 75.83%, with operating margin of 20.21%, and net profit margin of 12.56%.
Gross Margin75.83%
Operating Margin20.21%
Pretax Margin13.64%
Net Profit Margin12.56%
EBITDA Margin30.42%
EBIT Margin18.79%
Analyst Forecast
The average price target for Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is HK$62.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$62.00
Price Target Upside116.03% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast40.78%
EPS Growth Forecast410.73%